Tag: Janet Woodcock

Janet Woodcock

Washington Focus

Pressure Mounting for FDA Commissioner Among Reports that Califf Will Be Biden’s Choice

Pressure Mounting for FDA Commissioner Among Reports that Califf Will Be Biden’s Choice

Oct. 21, 2021—Nine months into President Joe Biden’s administration, he has still not nominated a candidate to take the helm at the Food and Drug Administration (FDA). Amid the COVID-19 pandemic and other pressing healthcare issues, the pressure is rising for a permanent FDA commissioner, but many of the frequently-named frontrunners for the position appear […]

Read more

Regulatory/FDA

FDA at Turning Point: Kate Rawson Explains

FDA at Turning Point: Kate Rawson Explains

June 11, 2021 – The Food and Drug Administration (FDA) “is really central, not only to product approvals, but to what [medical product companies] can say in terms of marketing,” according to Prevision Policy Senior Editor Kate Rawson. Rawson, who spoke June 4 at a Coalition for Healthcare Communication (CHC) webinar, “What’s Ahead for the […]

Read more

Regulatory/FDA

The Real FDA Leadership Story Is New CDER Director Dr. Patrizia Cavazzoni

The Real FDA Leadership Story Is New CDER Director Dr. Patrizia Cavazzoni

June 7, 2021 — Despite ongoing speculation about who will be the next Commissioner of the Food and Drug Administration (FDA), “the real leadership story is at CDER,” the Center for Drug Evaluation and Research, according to Kate Rawson, senior editor of Prevision Policy. As Rawson explained during a June 4 webinar on “What’s Ahead […]

Read more

Regulatory/FDA

FDA Clamps Down on Company for Failing to Submit Clinical Trial Data to ClinicalTrials.gov

FDA Clamps Down on Company for Failing to Submit Clinical Trial Data to ClinicalTrials.gov

May 3, 2021 – Although the Food and Drug Administration (FDA) has issued more than 40 “Pre-Notices of Noncompliance” to companies to encourage voluntarily compliance with a federal requirement to submit all clinical trial data to the ClinicalTrials.gov database, last week the agency issued its first “Notice of Noncompliance” to Acceleron Pharma for not complying […]

Read more

Regulatory/FDA

FDA Plans Expedited Approval Path for Modified COVID-19 Vaccines

FDA Plans Expedited Approval Path for Modified COVID-19 Vaccines

Feb. 8, 2021 – With growing concern about the spread of new COVID-19 variants, companies developing vaccine modifications will not have to “start at square one,” according to Food and Drug Administration (FDA) Acting Commissioner Janet Woodcock, M.D.. Because of early indications that the initial vaccines may have lower effectiveness against one or more of […]

Read more

Regulatory/FDA

Woodcock to Take Helm While Biden Considers FDA Commissioner Choice

Woodcock to Take Helm While Biden Considers FDA Commissioner Choice

Jan. 18, 2021 – Under the Biden administration, longtime Center for Drug Evaluation and Research (CDER) director and FDA veteran Janet Woodcock, M.D., has been tapped to serve as the acting commissioner of the Food and Drug Administration (FDA) after current FDA Commissioner Stephen Hahn, M.D., stepped down on Jan. 20. Media reports suggest that […]

Read more

Regulatory/FDA

FDA Leaders Highlight Issues, Opportunities of Real-world Data Post-marketing

FDA Leaders Highlight Issues, Opportunities of Real-world Data Post-marketing

May 6, 2019 — “It doesn’t just take a village, it takes an ecosystem,” Jeffrey Shuren, M.D., J.D., director of the Center for Devices and Radiological Health (CDRH), told the annual meeting of the Reagan-Udall Foundation for the FDA in Washington on May 2, highlighting the challenge of drawing upon a sufficiently broad range of […]

Read more